Hanmi Pharmaceutical Partner to Present 'Rolontis' Clinical Data at American Society of Clinical Oncology Conference

Hanmi Pharmaceutical Also Announces Clinical Results of 5 Synthetic New Drugs

[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical announced on the 6th that its partner Spectrum will present key clinical data on the neutropenia treatment biopharmaceutical 'Rolontis' and the innovative anticancer drug 'Poziotinib' at the American Association for Cancer Research (AACR), held online from the 10th to the 15th. The AACR is the world's largest cancer conference, with over 48,000 members from 127 countries.

On the 10th (local time), Spectrum will present Phase 2 clinical trial results led by Professor Xiuning Li, showing that administering Poziotinib twice daily to patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) exon 20 mutations increased safety and tolerability.

Additionally, Professor John Barrett will unveil a poster containing Phase 1 clinical trial results of Rolontis. The study investigated same-day administration of Rolontis on the day of chemotherapy in mice with neutropenia and early breast cancer patients, demonstrating enhanced recovery from neutropenia with this dosing regimen.

Hanmi Pharmaceutical and Spectrum plan to release detailed research results immediately following the AACR presentations.

Separately from Spectrum, Hanmi Pharmaceutical will also present preclinical and clinical results of five synthetic drugs under development, including immuno-oncology agents.

This content was produced with the assistance of AI translation services.